Chapter

Chemotherapy for metastatic prostate cancer

Cora N Sternberg and Guru Sonpavde

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

Published in print February 2010 | ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780191740251 | DOI: https://dx.doi.org/10.1093/med/9780199561421.003.0007

Series: Oxford Oncology Library

Chemotherapy for metastatic prostate cancer

Show Summary Details

Preview

Docetaxel-based chemotherapy has been shown to modestly extend life, relieve pain, and improve the quality of life in patients with metastatic castration-resistant prostate cancer

Current trials are attempting to build on the backbone of docetaxel by combining it with novel biologic agents

Trials are also investigating the role of docetaxel for earlier stages of prostate cancer

No standard second-line chemotherapy exists and such patients are candidates for trials. The increased understanding of the mechanisms of progressive castration-resistant prostate cancer is being translated into an increasing pipeline of novel therapies.

Chapter.  3427 words. 

Subjects: Radiation Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.